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Introduction
In the United States, lung cancer is the second most common cancer in men after prostate cancer and the second most common cancer in women after breast cancer. In 2013 an estimated 228,190 new cases of lung cancer were diagnosed in the United States, accounting for about 14% of all cancer diagnoses. 1 The incidence rate has been declining in men over the past 2 decades, but in women the incidence rate has just recently started to decrease. Lung cancer is the leading cause of cancer-related death among both men and women in the United States, and it accounts for more deaths than any other cancer in both sexes.
In 2013 approximately 159,480 deaths occurred, or about 27% of all cancer deaths. Lung cancer causes more deaths annually than prostate, breast, colon, and pancreatic cancers combined. 1 Non-small-cell lung cancer (NSCLC) represents more than 80% of lung cancer diagnoses and has an overall 5-year survival rate of approximately 16%, which decreases precipitously among patients diagnosed with latestage disease. 2, 3 An assessment of historical trends in patient survival is an important evaluation to determine the progress toward patient outcomes and reveal where advancements must be made. To date, few studies have evaluated survival trends over time in patients with lung cancer. The goal of this study was to assess changes in demographics and overall survival of NSCLC patients across 5 time periods spanning 22 years who were seen at Moffitt Cancer Center (MCC).
Material and Methods

Study Population
This analysis included 4,997 NSCLC patients who were treated at our institute between 1986 and 2008. The 5 periods that were selected for analysis were 1986 to 1988, 1991 to 1993, 1996 to 1998, 2001 to 2003, and 2006 to 2008. These time period ranges were selected to compare changes in demographics and overall survival within and across decades. Each study period included 3 years of patient data with a 2-to 3-year interval in between. This research was approved by the University of South Florida Institutional Review Board.
Cancer Registry Data
The primary source of data for this analysis was MCC's Cancer Registry, which abstracts information from patient electronic medical records on demographics, history of smoking, stage, histology, and treatment. Patients seen for second opinions are not included in the Cancer Registry database because they do not fall under current reportable state and/or federal guidelines. Follow-up for survival and vital status information occurs annually through passive and active methods. The Cancer Registry defines "first course of treatment" as all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence or death. For this analysis smoking status was categorized as self-reported current smoker, former smoker, or never-smoker. Where available, pathological TNM staging was utilized, and if these data were missing, we utilized clinical stage information.
Statistical Analysis
Pearson's chi-square was used to test for differences in the patient characteristics across the 5 time groups.
Overall survival was right-censored at 5 years, and survival analyses were performed using Kaplan-Meier survival curves and the log-rank statistic. Multivariable Cox proportional hazard regression was utilized to generate hazard ratio (HR) and 95% confidence interval (CI) for each time period. All statistical analyses were performed using R version 2.14 (R Project for Statistical Computing, www.rproject.org). Complete follow-up data were not available on all patients. The number of patients with complete follow-up data per time period is noted in Table 2 and Fig 1. From 1986 to 2008 among all NSCLC patients, the median survival time statistically significantly increased (P < .001) from 1.09 years (95% CI, 0.95-1.34) to 2.27 years (95% CI, 2.07-2.46), and the overall 5-year survival rate significantly increased (P < .001) from 14.7% to 31.1% ( 
Results
For this analysis
Discussion
This analysis of Cancer Registry data from 5 time periods of lung cancer patients at our institute demonstrates statistically significant changes in demographics and survival of NSCLC patients over the past 22 years. Most importantly, from 1986 to 2008, the overall median survival time and overall 5-year survival rate have both more than doubled. Additionally, we observed statistically significant increases in stage-specific 5-year survival rates over the 5 time periods.
The most recent Surveillance, Epidemiology, and End Results (SEER) monograph on lung cancer, published in 2007, reported overall and stagespecific survival rates based on patients diagnosed between 1998 to 2001 from 12 SEER areas. 4 Since none of the 5 time periods in our study completely overlapped with the time period in the SEER study, we explored the 1998 to 2001 time period in our data so we could make comparisons. The overall 5-year survival for SEER was 15.5% vs 25.0% in our data, and the stage-specific rates in the SEER study vs our study were 56.9% vs 52.4% for stage I, found only a 2.6% absolute difference in the 5-year age-standardized relative survival ratios for all lung cancers combined. An earlier study conducted in Canada 8 analyzed survival trends across 5 time periods (1969 to 1973, 1974 to 1978, 1979 to 1983, 1984 to 1988, and 1989 to 1991) and found no significant differences across the study periods. Unfortunately, neither Canadian study presented stage-specific results and combined all lung cancers together rather than focusing on specific histological subtypes.
The multivariable models in the present analysis revealed that older patients, men, current smokers, and late-stage patients were associated with an increased risk of death. The findings for age, sex, and smoking status have been reported in previous studies, [3] [4] [5] and tumor stage is a well-documented prognostic and predictive factor for NSCLC. [9] [10] [11] First course of treatment with radiation was also associated with an increased risk of death. Kachroo et al 8 reported a similar finding for radiation therapy where patients treated with radiation only were associated with a 3.9-fold (95% CI, 1.12-13.33) increased risk of death. Lung cancer patients who receive radiotherapy typically have more advanced disease (eg, postoperative stage IIIA, unresectable stage IIIA/B, stage IV). Additionally, some early-stage lung cancer patients are also referred for radiotherapy if they have poor performance status and are not surgical candidates. Thus, the increased risk of death among patients who receive radiotherapy likely reflects the poor performance status and inherent poor prognosis of the patients rather than the treatment itself. We also observed that surgery-only patients were generally associated with a reduced risk of death. This finding is not unexpected since surgery is the typical treatment for early-stage NSCLC patients with good performance status.
A few limitations must be acknowledged about this study. First, we acknowledge the possible lack of generalizability of our study population because the lung cancer patients in this analysis were derived from a single cancer care center and were composed of mostly non-Hispanic whites. Hence, the results may not be generalizable to community practices or even to other cancer centers. However, we must consider that lung cancer patients at a tertiary cancer center like MCC could represent more complex cases, and thus our 5-year survival rates could be conservative. This is speculation since we do not have demographic and 5-year survival data for regional practices. Additionally, our analysis was limited to Cancer Registry data, which does not include a comprehensive and systematic assessment of lung cancer risk factors such as detailed smoking history, family history of cancer, occupational exposures, and medical history. The data abstracted by Cancer Registry are limited to information that is available in patient medical records.
Conclusions
This analysis demonstrated important temporal changes in the demographics and improvements in overall survival of non-small-cell lung cancer patients treated at Moffitt Cancer Center from 1986 to 2008. The 5-year survival rates and median survival times of patients diagnosed with non-small-cell lung cancer have significantly improved across all stages, including late-stage disease. The observed improvement in lung cancer survival over the last 22 years is likely attributed to several factors including advancements in surgery, chemotherapy regimens, management of comorbidities, and a slightly higher percentage of early-stage patients who are more amendable to treatment. Further study is required to assess potential temporal changes in targeted molecular-based therapies, advancements in surgical procedures, and patients enrolled into chemotherapy trials.
